Disease Domain | Count |
---|---|
Neoplasms | 8 |
Infectious Diseases | 5 |
Nervous System Diseases | 2 |
Hemic and Lymphatic Diseases | 2 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 10 |
Fusion protein | 2 |
Synthetic peptide | 2 |
Recombinant polypeptide | 1 |
Chemical drugs | 1 |
Target |
Mechanism DHODH inhibitors |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism PDL1 inhibitors |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism HDAC inhibitors |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date20 Jul 2024 |
Sponsor / Collaborator |
Start Date16 Oct 2019 |
Sponsor / Collaborator |
Start Date01 Mar 2013 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
HLY-0019 ( HDACs ) | Neoplasms More | Preclinical |
WWQ-131 ( JAK2 ) | Myeloproliferative Disorders More | Preclinical |
Secondary Amine Pendant β-Peptide Polymers | Bacterial keratitis More | Preclinical |
isobavachalcone ( DHODH ) | Acute Myeloid Leukemia More | Preclinical |
βLys50HG50 | MRSA - Methicillin resistant Staphylococcus aureus infection More | Preclinical |